共 381 条
[11]
Zelenetz AD(2018)Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy Br J Haematol 183 364-2306
[12]
Gordon LI(2017)Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy Blood 130 2295-1554
[13]
Abramson JS(2021)Reactions related to CAR-T cell therapy Front Immunol 12 663201-68
[14]
Advani RH(2021)Neurological updates: neurological complications of CAR-T therapy J Neurol 268 1544-e162
[15]
Bartlett NL(2022)Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a scoping review Hemasphere 6 e802-173
[16]
Caimi PF(2022)Correction to: quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study Ann Hematol 101 333-281
[17]
Chang JE(2017)A qualitative study of the post-treatment experiences and support needs of survivors of lymphoma Eur J Oncol Nurs 28 62-544
[18]
Chavez JC(2021)The unique symptom burden of patients receiving CAR T-cell therapy Semin Oncol Nurs 37 151216-112
[19]
Christian B(2019)Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities Biol Blood Marrow Transplant 25 e155-486
[20]
Fayad LE(2017)Patient-reported outcomes in cancer survivorship Acta Oncol 56 166-62